Literature DB >> 30654682

Metabolism study of hesperetin and hesperidin in rats by UHPLC-LTQ-Orbitrap MSn.

Qishu Jiao1, Lulu Xu1, Lijuan Jiang1, Yanyan Jiang1, Jiayu Zhang2, Bin Liu1.   

Abstract

1. Hesperidin (HPD) and hesperetin (HPT), as a kind of flavonone compounds, are abundant in citrus fruits with various pharmacological effects. HPD and HPT are not always consistent in some biological activities, even if they have the same skeletal structure. 2. The aim of this study was to screen and identify HPT and HPD metabolites in rats using UHPLC-LTQ-Orbitrap MSn, compare the possible metabolism and provide the research basis for further understanding the similarities and differences in pharmacodynamics and pharmacokinetics of HPT and HPD. 3. A total of 17 and 52 metabolites were identified in rats after oral administration of HPT or HPD, respectively. 4. Three of HPT and HPD metabolites, glucuronidation, sulfation and diglucuronidation of HPT, were the same and could be the active components for the same pharmacodynamic action of them. 5. We could find prototype in the urine sample of HPD group, but no prototypes in any samples of HPT group. There were hardly any general phase I metabolites of HPT, while 33 phase I metabolites of HPD could be identified. These data suggested that the poorer bioavailability of HPD compared with HPT.

Entities:  

Keywords:  UHPLC-LTQ-Orbitrap mass spectrometer; comparison study; hesperetin; hesperidin; metabolism

Year:  2019        PMID: 30654682     DOI: 10.1080/00498254.2019.1567956

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  6 in total

1.  Hesperidin Inhibits Lung Cancer In Vitro and In Vivo Through PinX1.

Authors:  Yang Yao; Mingyue Lin; Zhujun Liu; Mengyang Liu; Shiheng Zhang; Yukun Zhang
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

Review 2.  Effect of Hesperidin on Cardiovascular Disease Risk Factors: The Role of Intestinal Microbiota on Hesperidin Bioavailability.

Authors:  Anna Mas-Capdevila; Joan Teichenne; Cristina Domenech-Coca; Antoni Caimari; Josep M Del Bas; Xavier Escoté; Anna Crescenti
Journal:  Nutrients       Date:  2020-05-20       Impact factor: 5.717

Review 3.  Hesperidin: A Therapeutic Agent For Obesity.

Authors:  Haijun Xiong; Jin Wang; Qian Ran; Guanhua Lou; Chengyi Peng; Qingxia Gan; Ju Hu; Jilin Sun; Renchuan Yao; Qinwan Huang
Journal:  Drug Des Devel Ther       Date:  2019-11-12       Impact factor: 4.162

Review 4.  Potential roles of gut microbes in biotransformation of natural products: An overview.

Authors:  Yucui Zhao; Xinqin Zhong; Junyuan Yan; Congying Sun; Xin Zhao; Xiaoying Wang
Journal:  Front Microbiol       Date:  2022-09-29       Impact factor: 6.064

Review 5.  Metabolomics Technologies for the Identification and Quantification of Dietary Phenolic Compound Metabolites: An Overview.

Authors:  Anallely López-Yerena; Inés Domínguez-López; Anna Vallverdú-Queralt; Maria Pérez; Olga Jáuregui; Elvira Escribano-Ferrer; Rosa M Lamuela-Raventós
Journal:  Antioxidants (Basel)       Date:  2021-05-25

6.  Thiolated Chitosan as an Intestinal Absorption Carrier with Hesperidin Encapsulation for Obesity Treatment.

Authors:  Tzu-Chien Chen; Yu-Yu Ho; Rui-Chian Tang; Yong-Chen Ke; Jhih-Ni Lin; I-Hsuan Yang; Feng-Huei Lin
Journal:  Nutrients       Date:  2021-12-09       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.